BioCentury
ARTICLE | Clinical News

PF-06263507: Phase I started

September 2, 2013 7:00 AM UTC

Pfizer began a 2-part, open-label, dose-escalation, U.S. Phase I trial to evaluate IV PF-06263507 in 21-day cycles in about 75 patients with advanced solid tumors. The first part will determine the ma...